22:03 , Dec 30, 2016 |  BC Week In Review  |  Company News

Transgene, ElsaLys deal

Transgene granted ElsaLys exclusive, worldwide rights, except in greater China, to develop and commercialize preclinical immuno-oncology candidate ELB041 (formerly TG3003), a human mAb against CD115 . ElsaLys hopes to begin clinical development before year end...
07:00 , Aug 6, 2012 |  BC Week In Review  |  Company News

Transgene, Tasly Pharmaceutical deal

Tasly will invest €5.3 million ($6.5 million) in the JV while Transgene will contribute €2.6 million ($3.2 million). Transgene will also contribute IP rights and appoint a CEO of the JV. In February, Transgene said...